Evidence map›Paper›PMID 28545467›Full record

ArticleMicrobial cell factories2017

Expression of deleted, atoxic atypical recombinant beta2 toxin in a baculovirus system and production of polyclonal and monoclonal antibodies.

Anna Serroni, Chiara Francesca Magistrali, Giovanni Pezzotti, Luca Bano, Martina Pellegrini, Giulio Severi, Chiara Di Pancrazio, Mirella Luciani, Manuela Tittarelli, Silvia Tofani and 1 more

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anna SerroniIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy.
Chiara Francesca MagistraliIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy.
Giovanni PezzottiIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy.
Luca BanoIstituto Zooprofilattico Sperimentale delle Venezie, Vicolo Mazzini 4, Villorba Di Treviso, Italy.
Martina PellegriniIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy.
Giulio SeveriIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy.
Chiara Di PancrazioIstituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G.Caporale", Teramo, Italy.
Mirella LucianiIstituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G.Caporale", Teramo, Italy.
Manuela TittarelliIstituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G.Caporale", Teramo, Italy.
Silvia TofaniIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy.
Antonio De GiuseppeIstituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Via G. Salvemini 1, 06126, Perugia, Italy. a.degiuseppe@izsum.it.
Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche · ITIstituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise G. Caporale · ITIstituto Zooprofilattico Sperimentale delle Venezie · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClostridium perfringens is an important animal and human pathogen that can produce more than 16 different major and minor toxins. The beta-2 minor toxin (CPB2), comprising atypical and consensus variants, appears to be involved in both human and animal enterotoxaemia syndrome. The exact role of CPB2 in pathogenesis is poorly investigated, and its mechanism of action at the molecular level is still unknown because of the lack of specific reagents such as monoclonal antibodies against the CPB2 protein and/or the availability of a highly purified antigen. Previous studies have reported that purified wild-type or recombinant CPB2 toxin, expressed in a heterologous system, presented cytotoxic effects on human intestinal cell lines. Undoubtedly, for this reason, to date, these purified proteins have not yet been used for the production of monoclonal antibodies (MAbs). Recently, monoclonal antibodies against CPB2 were generated using peptides designed on predicted antigenic epitopes of this toxin.

resultsIn this paper we report, for the first time, the expression in a baculovirus system of a deleted recombinant C-terminal 6xHis-tagged atypical CPB2 toxin (rCPB2

conclusionsThe high-throughput of purified atoxic recombinant CPB2 produced in insect cells, allowed to obtain monoclonal and polyclonal antibodies. The availability of these molecules could contribute to develop immunoenzymatic methods and/or to perform studies about the biological activity of CPB2 toxin.

Indexed as

Gene DeletionAntibodiesAntibodies, MonoclonalBacterial ToxinsBaculoviridaeGene Expression Regulation, BacterialRecombinant ProteinsAntibodiesAntibodies, MonoclonalBacterial Toxinscpb2 protein, Clostridium perfringensRecombinant ProteinsAtoxic rCPB2Δ1–25-His6Monoclonal antibodyNi2+ affinity chromatography

Identifiers

PMID28545467
PMCPMC5445335
OpenAlexW2619775107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.